These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 10488324)

  • 21. Aldosterone blockade in heart failure.
    Struthers AD
    J Renin Angiotensin Aldosterone Syst; 2004 Sep; 5 Suppl 1():S23-7. PubMed ID: 15526239
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Aldosterone, hypertension and heart failure: insights from clinical trials.
    Funder JW
    Hypertens Res; 2010 Sep; 33(9):872-5. PubMed ID: 20631715
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Cost-benefit analysis of spironolactone use in the treatment of chronic heart failure].
    Alvarez JS; Vílchez FG
    Rev Esp Cardiol; 2001 Feb; 54(2):175-80. PubMed ID: 11181306
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Spironolactone in left-sided heart failure: how does it fit in?
    Margo KL; Luttermoser G; Shaughnessy AF
    Am Fam Physician; 2001 Oct; 64(8):1393-8. PubMed ID: 11681781
    [TBL] [Abstract][Full Text] [Related]  

  • 25. What's old is new again. Spironolactone and heart failure.
    Lock M; Chun R
    Can Fam Physician; 1999 Nov; 45():2621-2. PubMed ID: 10587769
    [No Abstract]   [Full Text] [Related]  

  • 26. Aldosterone blockade over and above ACE-inhibitors in patients with coronary artery disease but without heart failure.
    Shah NC; Pringle S; Struthers A
    J Renin Angiotensin Aldosterone Syst; 2006 Mar; 7(1):20-30. PubMed ID: 17083070
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Spironolactone for heart failure.
    Med Lett Drugs Ther; 1999 Sep; 41(1061):81-2. PubMed ID: 10505071
    [No Abstract]   [Full Text] [Related]  

  • 28. [Antialdosteronic therapy in mild chronic heart failure: from AREA IN-CHF to EMPHASIS-HF].
    Boccanelli A
    Recenti Prog Med; 2010 Oct; 101(10):402-5. PubMed ID: 21137577
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Cost effectiveness of the use of spironolactone in the treatment of chronic heart failure].
    Soto Alvarez J; González Vilchez F
    An Med Interna; 2001 Aug; 18(8):421-5. PubMed ID: 11589080
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Eplerenone: new drug. Recent myocardial infarction with heart failure: a spironolactone me too.
    Prescrire Int; 2006 Apr; 15(82):46-9. PubMed ID: 16604728
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Aldosterone antagonist].
    Yamazaki T
    Nihon Rinsho; 2006 May; 64(5):917-20. PubMed ID: 16689374
    [No Abstract]   [Full Text] [Related]  

  • 32. Economic evaluation of the randomized aldactone evaluation study (RALES): treatment of patients with severe heart failure.
    Glick HA; Orzol SM; Tooley JF; Remme WJ; Sasayama S; Pitt B
    Cardiovasc Drugs Ther; 2002 Jan; 16(1):53-9. PubMed ID: 12085979
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [On the mechanism of action of antialdosterone compounds (aldactone and progesterone) in the treatment of cardiac edema].
    Gerasimova EN; Kononiachenko VA
    Ter Arkh; 1966 Apr; 38(4):112-8. PubMed ID: 5984655
    [No Abstract]   [Full Text] [Related]  

  • 34. Slow adoption of helpful heart failure drug. Many people who could benefit from spironolactone aren't getting it.
    Harv Heart Lett; 2010 Feb; 20(6):2. PubMed ID: 20376944
    [No Abstract]   [Full Text] [Related]  

  • 35. [Professor Bertram Pitt on therapy of heart failure after EMPHASIS. "Clear prognosis improvement" (interview by Dr. Med. Dirk Enecke)].
    Pitt B
    MMW Fortschr Med; 2010 Dec; 152(48):13. PubMed ID: 21222326
    [No Abstract]   [Full Text] [Related]  

  • 36. Rationale for the use of aldosterone antagonists in congestive heart failure.
    Rocha R; Williams GH
    Drugs; 2002; 62(5):723-31. PubMed ID: 11929327
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The spironolactone renaissance.
    Doggrell SA; Brown L
    Expert Opin Investig Drugs; 2001 May; 10(5):943-54. PubMed ID: 11322868
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Spironolactone as a cardio-protective drug].
    Yoshimura M
    Nihon Rinsho; 2007 May; 65 Suppl 5():107-9. PubMed ID: 17569309
    [No Abstract]   [Full Text] [Related]  

  • 39. [Therapy of heart insufficiency using aldosterone antagonists].
    Krauss J
    Z Allgemeinmed; 1973 Jul; 49(21):989-91. PubMed ID: 4756071
    [No Abstract]   [Full Text] [Related]  

  • 40. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators.
    Zannad F; Alla F; Dousset B; Perez A; Pitt B
    Circulation; 2000 Nov; 102(22):2700-6. PubMed ID: 11094035
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.